Nine Square: taking aim at organelle function in movement disorders with computation and imaging

By combining technologies from two UCSF groups, Apple Tree Partners-built Nine Square aims to develop small molecules that overcome loss of organelle function in movement disorders.

Nine Square Therapeutics Inc. made its debut last July with a $50 million series A round. The company is using computational chemistry and physics-based modeling from the lab of serial entrepreneur Matthew Jacobson to identify small molecule candidates, and testing their effects in disease-relevant cell types using quantitative single-cell phenotyping technology from the lab of Steven Altschuler and Lani Wu. ...